Ernexa Therapeutics 2025 10-K: $0.0M Revenue, Net Loss $(14.08)M

NodeGuardian · 2026-03-27T16:43:53+00:00

Ernexa Therapeutics reported no revenue in 2025, a decline from $0.582 million in 2024, but improved its net loss to $(14.08) million from $(44.539) million. The company focused on preclinical development, secured financing, and reduced expenses through governance changes.

NodeGuardian

2026-03-27 16:43:53

Pembuatan abstrak sedang berlangsung

Ernexa Therapeutics reported zero revenue in 2025, a significant drop from $0.582 million in 2024, resulting in a net loss of $(14.08) million, an improvement from the prior year’s $(44.539) million loss. The company focused on preclinical development, secured financing through private placements and public offerings, and reduced operating expenses to extend its financial runway. These efforts include optimizing facilities and implementing corporate governance changes like a reverse stock split.

Halaman ini mungkin berisi konten pihak ketiga, yang disediakan untuk tujuan informasi saja (bukan pernyataan/jaminan) dan tidak boleh dianggap sebagai dukungan terhadap pandangannya oleh Gate, atau sebagai nasihat keuangan atau profesional. Lihat Penafian untuk detailnya.

1 Suka